Sentences with phrase «myeloma cells also»

The myeloma cells also damage and weaken the bone.

Not exact matches

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Heacell research at Moores Cancer Center at UC San Diego Health.

They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.

They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem cells in multiple myeloma models.

The researchers also tested a Runx2 knock - down variant of a human multiple myeloma cell line and found that it produced significantly less tumor growth in immunodeficient mice than the original human multiple myeloma cells.

Dr. Goodman is also one of the lead contributors to the Intergroup trial of stem cell transplantation and multiple myeloma.

Myeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antiMyeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antimyeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antimyeloma — is a cancer that originates in plasma cells, a type of white blood cell that makes antibodies.

They fused mouse B cells — antibody - producing cells of the immune system — with human myeloma (also known as B cell cancer) cell lines in a new technique called hybridoma technology.

Myeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antiMyeloma — also referred to as multiple myeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antimyeloma or plasma cell myeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antimyeloma — is a cancer that originates in plasma cells, a type of white blood cell that make antibodies.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

Though monoclonal antibodies were a model product in his 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno - modulants and vaccines with different expression systems such as hybridoma, myeloma, CHO, BHK, insect - cell / baculovirus, adherent animal and human cells.

sorafenib induces cell death in human myeloma cell lines in a laboratory environment by preventing a certain kind of protein - level activity, an effect that also was achieved when the myeloma cells had developed a resistance to